Report overview
This report contains market size and forecasts of Cancer Tubulin Inhibitors in global, including the following market information:
Global Cancer Tubulin Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cancer Tubulin Inhibitors Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Cancer Tubulin Inhibitors companies in 2021 (%)
The global Cancer Tubulin Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Docetaxel Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Tubulin Inhibitors include Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, Genentech, Immunogen and Modra Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Tubulin Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Tubulin Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Tubulin Inhibitors Market Segment Percentages, by Type, 2021 (%)
Docetaxel
Trastuzumab Emtansine
Abraxane
Brentuximab Vedotin
Cabazitaxel
Global Cancer Tubulin Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Tubulin Inhibitors Market Segment Percentages, by Application, 2021 (%)
Non Small Cell Lung Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Ovarian Cancer
Global Cancer Tubulin Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Tubulin Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Tubulin Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cancer Tubulin Inhibitors revenues share in global market, 2021 (%)
Key companies Cancer Tubulin Inhibitors sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Cancer Tubulin Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abraxis Biosciences
Agensys
Amgen
Celgene
Eagle Pharmaceuticals
Endocyte
Genentech
Immunogen
Modra Pharmaceuticals
Pierre Fabre
Roche
Sanofi-Aventis
Seattle Genetics
Tocris Bioscience
